Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 5;41(44):4905–4915. doi: 10.1038/s41388-022-02483-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A DEGs that show increased (log2FC > 1 and padj <0.05) expression in every clone for each ESR1 mutation were overlapped in the Venn diagram. The 11 genes used in signature development are listed. The 6 genes developed from analysis of the POG570 mutant ESR1 cancers are highlighted in bold. B Expression of the 6-gene list is elevated in ESR1 mutant metastatic (POG570, MET500) and primary (Dahlgren) breast cancer. The number of ER + patients with WT and mutant ESR1 are shown in parentheses. The Mann-Whitney test was used for significance determination. C, D Kaplan–Meier plots of survival for ER + breast cancer patients with ESR1 mutations. The hazard ratios (HR), together with 95% confidence intervals (in brackets) and p value from the log rank test is shown in each panel; ‘n’ is the number of samples in each group.